Half-year report · Q2
4671.TEDINET S100UP43
Period2024-04-01 → 2024-09-30
Filed2024-11-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥21.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥43.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥21.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥974m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥851m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.0bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥2.3bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥931m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥794m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥629m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥794m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥629m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥36.2bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥36.4bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥36.7bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥10.2bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥10.4bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥25.9bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥26.0bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥26.0bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.6bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.1bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.6bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.1bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.2bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.6bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥73m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥860m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥74.46 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥151.72 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.29 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥74.25 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥150.9 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥56.14 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 71.4% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥176m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥13.1bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥13.1bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥726m |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥7.7bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥7.7bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥347m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥538m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥538m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥76m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥21.4bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥21.4bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥270m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥13.0bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥13.0bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥689m |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥385m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥449m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥449m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥46m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥21.3bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥21.3bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 522
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -0 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 13095000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 7733000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E04982-000ICTBusinessReportableSegmentsMember | 538000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 21367000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -0 | JPY |
| Net sales | CurrentYTDDuration | 21366000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 726000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 347000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E04982-000ICTBusinessReportableSegmentsMember | 76000000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 1150000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -176000000 | JPY |
| Operating income | CurrentYTDDuration | 974000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)近畿財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-11-12 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第38期中（自 2024年４月１日 至 2024年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社ファルコホールディングス | |
| Company name in english cover page | FilingDateInstant | FALCO HOLDINGS Co., Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 社長執行役員 安田 忠史 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)京都市左京区聖護院蓮華蔵町44番地３（同所は登記上の本店所在地で実際の管理業務は「最寄りの連絡場所」で行っております。） | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | － | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | － | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)大阪市中央区内平野町１丁目３番７号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | ０６－７６３２－６１５０ | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)執行役員管理室長 黒田 修平 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E04982 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 46710 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社ファルコホールディングス | |
| Filer name in english | FilingDateInstant | FALCO HOLDINGS Co., Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Current period end date | FilingDateInstant | 2024-09-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Comparative period end date | FilingDateInstant | 2023-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Next fiscal year start date | FilingDateInstant | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |